Asher Biotherapeutics has announced an agreement with AstraZeneca to supply etakafusp alfa for a global study to evaluate its safety and early efficacy as a first-line treatment in combination with rilvegostomig in patients with advanced or metastatic NSCLC. AstraZeneca will sponsor and operationalize the study while Asher Bio retains full ownership of etakafusp alfa and will supply it at no cost.